Tags

Type your tag names separated by a space and hit enter

Temozolomide-Capecitabine (TemCap) chemotherapy for Neuroendocrine Neoplasms (NENs): the dilemma of treatment duration.

Abstract

n/a, this is a letter to the editor.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Letter

Language

eng

PubMed ID

31527383

Citation

Lamarca, Angela, et al. "Temozolomide-Capecitabine (TemCap) Chemotherapy for Neuroendocrine Neoplasms (NENs): the Dilemma of Treatment Duration." Neuroendocrinology, 2019.
Lamarca A, Barriuso J, McNamara MG, et al. Temozolomide-Capecitabine (TemCap) chemotherapy for Neuroendocrine Neoplasms (NENs): the dilemma of treatment duration. Neuroendocrinology. 2019.
Lamarca, A., Barriuso, J., McNamara, M. G., Hubner, R. A., Manoharan, P., Mansoor, W., & Valle, J. W. (2019). Temozolomide-Capecitabine (TemCap) chemotherapy for Neuroendocrine Neoplasms (NENs): the dilemma of treatment duration. Neuroendocrinology, doi:10.1159/000503392.
Lamarca A, et al. Temozolomide-Capecitabine (TemCap) Chemotherapy for Neuroendocrine Neoplasms (NENs): the Dilemma of Treatment Duration. Neuroendocrinology. 2019 Sep 17; PubMed PMID: 31527383.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Temozolomide-Capecitabine (TemCap) chemotherapy for Neuroendocrine Neoplasms (NENs): the dilemma of treatment duration. AU - Lamarca,Angela, AU - Barriuso,Jorge, AU - McNamara,Mairéad G, AU - Hubner,Richard A, AU - Manoharan,Prakash, AU - Mansoor,Wasat, AU - Valle,Juan W, Y1 - 2019/09/17/ PY - 2019/09/16/received PY - 2019/09/16/accepted PY - 2019/9/19/entrez JF - Neuroendocrinology JO - Neuroendocrinology N2 - n/a, this is a letter to the editor. SN - 1423-0194 UR - https://www.unboundmedicine.com/medline/citation/31527383/Temozolomide-Capecitabine_(TemCap)_chemotherapy_for_Neuroendocrine_Neoplasms_(NENs):_the_dilemma_of_treatment_duration L2 - https://www.karger.com?DOI=10.1159/000503392 DB - PRIME DP - Unbound Medicine ER -